One of India's leading pharma companies, Dr Reddy's ($546 million) primarily manufactures and markets API (Bulk Actives), finished dosages and biologics globally, with a focus on the US, Europe, India and Russia. In the recent past, the company stepped up its biotechnology focus. Its biologics business division focuses on developing recombinant technology. It has developed an in-house biogeneric, GRASTIM, in India. This is human Granulocyte Colony Stimulating Factor (hG-CSF), a recombinant protein used in chemotherapy-induced neutropenia and in bone marrow transplantation.

The recombinant proteins technology platform is its core competency. The company's 2005-06 revenues in the critical care and biotechnology segment stood at Rs 69.1 crore, an increase of 31 percent. The increase is mainly on account of growth in its critical care division by Rs 11 crore driven by growth in revenues from exports by Rs 6.9 crore as well as growth in revenues from India by Rs 4.1 crore. The biotech portion is estimated to be close to Rs 40 crore.